PharmaVOICE
116 FOLLOWERS
PharmaVOICE is a resource for life-sciences executives and other healthcare-service related professionals. The primary research are made of by executive and corporate management from pharmaceutical, biotechnology, drug delivery, marketing communications, clinical services, contract research, drug development, and information technology companies, as well as other industry sectors.
PharmaVOICE
7h ago
Pricey gene therapies promise great benefit to patients but pose a threat to the payer landscape — ICER and a Tufts think tank are offering potential solutions ..read more
PharmaVOICE
1d ago
The FDA’s newly launched Center for Clinical Trial Innovation potentially opens the door for more efficient and expanded AI use, but leaves pharmas wanting more guidance ..read more
PharmaVOICE
2d ago
From resurrecting an extinct species to improving regenerative medicines with plant-based materials, these biotechs are on the leading edge of science ..read more
PharmaVOICE
2d ago
From its landmark CRISPR approval to its potential breakthrough drug for pain, Vertex’s development approach, led by chief scientific officer Dr. David Altshuler, is paying off ..read more
PharmaVOICE
3d ago
Michelle Werner shares how the lessons from her resume — and personal experience — are driving her work with novel therapeutics ..read more
PharmaVOICE
3d ago
The company's schizophrenia drug picked up in its $14 billion acquisition of Karuna Therapeutics recently generated positive long-term data from its phase 3 program.
  ..read more
PharmaVOICE
6d ago
Dr. Jeremy Levin, CEO of Ovid Therapeutics, explains how scientific advances have converged to create a new era of drug development potential ..read more
PharmaVOICE
1w ago
From popular weight loss drugs to lifesaving cancer therapies, recent pharma deals show the industry is doubling down on manufacturing capacity to meet demand ..read more
PharmaVOICE
1w ago
While the company is eager to diversify, CEO Chris Viehbacher said that in the near-term any dealmaking would likely focus on collaborations and early-stage assets ..read more
PharmaVOICE
1w ago
After a successful mid-stage study, the companies aim to upend traditional wet AMD treatments with a one-time gene therapy ..read more